Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical is supported by a durable orphan-drug franchise, anchored by Crysvita’s $2B+ global sales potential and a broad portfolio that includes Dojolvi and Mepsevii, while its collaboration structure still allows it to capture about one quarter of Crysvita profits. The outlook is further strengthened by what appears to be a meaningful capital catalyst, with two PRVs that could collectively generate about $400M in non-dilutive capital, alongside expectations that reimbursement dynamics will not prevent high penetration across an estimated ~25% of the worldwide prevalent pool. Longer term, the company’s deep gene-therapy pipeline, including DTX401, UX701, and DTX301, plus planned expense reductions, supports upside from both future clinical catalysts and improved operating leverage.

Ultragenyx Pharmaceutical is facing a negative fundamental backdrop because its base commercial drugs may deliver lower-than-expected revenue, fail to meet guidance, and face meaningful competition from marketed and late-stage therapies, while patient reluctance to switch treatments may limit uptake. Its pipeline risk is also elevated, as clinical trial delays in rare diseases can materially push back sales estimates and recent setbacks such as the ASPIRE failure for GTX-102 remove a major growth driver, leading to lower modeled revenues and reduced profitability expectations. On top of that, high operating expenses, capital intensity, and reimbursement pressure for expensive gene therapies create additional financial strain and heighten the chance that clinical, regulatory, or commercial setbacks will prevent forecasts from materializing.